Peptide Protocol Answers: Clinical Q&A on GHK, Retatrutide, MOTS-C

The Six Peptide Questions Your Doctor Should Be Able to Answer

Over the past month, listeners sent in questions that reveal a critical gap: most clinicians prescribing peptides lack the mechanistic knowledge to troubleshoot non-response, optimize timing, or understand endocrine interactions. Here are the six most important questions—answered.

1. Kisspeptin + TRT in Women: Mechanism and Protocol

Kisspeptin (or kisspeptin-10, a.k.a. metastin) is a GnRH-stimulating neuropeptide. It operates upstream of the hypothalamic-pituitary-gonadal (HPG) axis. In women on testosterone replacement therapy, exogenous testosterone suppresses LH and FSH through negative feedback at the hypothalamus and anterior pituitary. Kisspeptin works differently: it directly stimulates GnRH neurons, potentially restoring cycle dynamics or ovulatory capacity even in the presence of exogenous androgen.

The clinical question: Should you use kisspeptin with TRT, or instead of it? Answer: depends on goal. If the goal is virilization or sustained androgenization, kisspeptin is additive—it doesn't replace TRT. If the goal is to restore fertility while minimizing long-term testosterone exposure, kisspeptin may allow TRT dose reduction. Baseline labs must include: total testosterone, free testosterone, LH, FSH, E2 (estradiol), and a pelvic ultrasound if fertility is the goal. Dosing: 0.5–2 mg IV/SC daily. Protocol typically requires 8–12 weeks to assess response.

Key safety point: Kisspeptin can increase estrogen production via aromatization of testosterone. Monitor E2 closely. If E2 rises above 50 pg/mL, consider a low-dose aromatase inhibitor (AI) like anastrozole 0.25 mg every 3 days.

2. PCOS in Teens and Early 20s: When Peptides Are Premature

Polycystic ovarian syndrome in adolescents is an endocrine diagnosis first, and a metabolic syndrome second. Before reaching for GLP-1 agonists (tirzepatide, semaglutide) or other peptide therapeutics, establish:

1. Baseline hormonal profile: Total and free testosterone, DHEA-S, LH, FSH, prolactin, TSH, T3 (reverse and free), 17-OHP (to rule out late-onset CAH).
2. Metabolic labs: Fasting glucose, insulin (fasting and 2-hour post-75g OGTT), HbA1c, lipid panel.
3. Insulin resistance severity: Calculate HOMA-IR (fasting insulin × fasting glucose / 405). HOMA-IR > 2.5 = clinical insulin resistance.

For teens with PCOS and mild insulin resistance, first-line therapy is still: inositol (4g myo-inositol + 1g d-chiro-inositol daily), metformin (500–2000 mg daily, divided), and diet modification (low-glycemic, adequate protein, omega-3 supplementation). Peptides like tirzepatide are reserved for PCOS with overt type 2 diabetes or HbA1c > 6.5% despite lifestyle and metformin.

Why wait? GLP-1 agonists suppress appetite and can worsen already-restricted eating in young women. Long-term data on GLP-1 use in adolescents is sparse. Start with evidence-based metabolic support first.

3. Retatrutide vs. Tirzepatide: Max Dose and Response Plateau

Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist. Tirzepatide is dual GLP-1/GIP. Retatrutide's addition of glucagon receptor signaling theoretically enhances thermogenesis and hepatic glucose control, but comes at a cost: gastrointestinal side effects plateau harder, and nausea/vomiting rates are higher at equivalent doses.

Tirzepatide max dose: 15 mg weekly (approved). Some clinicians use 20 mg weekly off-label, but efficacy gain is marginal and adverse events increase.

Retatrutide max dose: 12 mg weekly (as of 2024). This is NOT equivalent to tirzepatide 15 mg. The glucagon component creates a non-linear dose-response curve. Response typically plateaus between 8–12 mg.

The practical answer: If a patient maxes out tirzepatide (15 mg × 12–16 weeks) and plateaus in weight loss, switching to retatrutide may unlock an additional 5–10% weight reduction. But baseline labs (HbA1c, lipids, kidney function, pancreatic enzymes) must be repeated. Patients over 60 or with any renal impairment (eGFR < 60) should stay below 10 mg retatrutide.

4. MOTS-C Non-Responders: When to Investigate Further

MOTS-C is a mitochondrial-derived peptide with insulin-sensitizing and metabolic activity. It binds to formyl peptide receptor 2 (FPR2) on insulin-responsive tissues. In responders, MOTS-C (typically 400 mcg SC daily or 3×/week) lowers insulin, improves HbA1c by 0.5–1.5%, and increases resting metabolic rate.

Non-response occurs in:

• Severe insulin resistance (HOMA-IR > 5): MOTS-C works best when the pancreas can still produce insulin. If beta-cell exhaustion is advanced, MOTS-C alone is insufficient. Add metformin, berberine, and reassess after 12 weeks.
• Hypothyroidism: Low T3 and T4 blunt metabolic peptide activity. Check TSH, free T3, free T4. Optimize thyroid first.
• Chronic cortisol elevation: High cortisol antagonizes insulin sensitivity and suppresses mitochondrial function. Measure 24-hour urinary cortisol and late-night salivary cortisol. If elevated, consider phosphatidylserine (400 mg before bed) or ashwagandha (600 mg daily).
• Poor mitochondrial health: MOTS-C requires functional mitochondria to exert its effect. Supplement with CoQ10 (300 mg daily), alpha-lipoic acid (600 mg daily), and NAC (1200 mg daily).

Dosing for non-responders: Do not increase MOTS-C dose above 400 mcg/dose. Instead, extend duration to 16 weeks minimum before reassessing. Combine with magnesium glycinate (300–400 mg nightly) and omega-3 (2–3g EPA+DHA daily) to restore mitochondrial membrane integrity.

5. Dihexa for Alzheimer's: Preclinical Promise, No Clinical Data Yet

Dihexa is a brain-derived neurotrophic factor (BDNF) mimetic peptide. In rodent models of Alzheimer's disease, dihexa crosses the blood-brain barrier and prevents cognitive decline, amyloid-beta accumulation, and tau phosphorylation. The mechanism is exquisite: dihexa binds to tropomyosin receptor kinase B (TrkB), activating the same downstream pathways as endogenous BDNF.

The critical caveat: No human clinical trials have been completed. All evidence is in vitro or murine. Dihexa is available only through research suppliers or select offshore clinics. Insurance will not cover it. Off-label use is legally risky.

A responsible approach: If a patient is interested in BDNF upregulation for cognitive health, recommend evidence-based interventions first: aerobic exercise (strongest BDNF stimulus), intermittent fasting, ketogenic diet, or pharmaceutical-grade NAC (1200 mg daily). If considering dihexa, require cognitive testing at baseline (MMSE or MoCA) and neuroimaging (MRI or PET-amyloid). Retest every 6 months. Baseline labs: complete metabolic panel, lipids, ApoE genotype if available.

6. GHK and AHK for Skin, Collagen, and Systemic Health

GHK-Cu (copper-peptide) and its variant AHK-Cu are collagen-stimulating peptides. Both upregulate matrix metalloproteinase inhibitors (TIMPs) and suppress pro-inflammatory cytokines in skin fibroblasts. Systemic benefit is debated.

Topical GHK: 0.1–1% in cream or serum. Data supports improved skin elasticity, reduced wrinkle depth, and increased collagen I and III deposition after 12 weeks. Safe, minimal absorption.

Systemic GHK (IV/IM): 1–5 mg weekly. Proposed benefits include improved wound healing, reduced joint inflammation, and enhanced skin hydration. Mechanism: GHK upregulates HIF-1α (hypoxia-inducible factor), promoting angiogenesis and collagen remodeling. Limited human data; most evidence is in vitro.

Synergy with collagen and vitamin C: GHK works synergistically with exogenous collagen (10g daily hydrolyzed collagen peptides) and ascorbic acid (500–1000 mg daily). The combination accelerates collagen synthesis. Add NAC (1200 mg daily) to reduce cross-linking and preserve collagen flexibility.

Safety: GHK-Cu is well-tolerated. Monitor for copper overload (rare); baseline serum copper and ceruloplasmin are optional but prudent if using > 5 mg/week long-term.

Bottom Line

Peptide therapy demands mechanistic literacy, baseline lab work, and dose precision. Most non-responses reflect either incomplete endocrine assessment, suboptimal synergistic supplementation, or unrealistic timelines. Require 8–12 weeks minimum before declaring failure. Repeat relevant labs at the 6-week and 12-week marks. Integrate peptides into a foundation of sleep, training, stress management, and targeted supplementation. Peptides amplify good biology; they do not create it.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.